ArriVent BioPharma, Inc. AVBP | NASDAQ
|2026-09-09
Next Earnings: Nov 16, 2026
Company Overview:
2.8 Year AVBP Performance Metrics:
Build Custom Charts
AVBP Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for AVBP
Based on past 2.8-year performance, here are AVBP growth metrics:
Share price CAGR of -14.24%
Dividend CAGR of +0%
Using AVBP CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AVBP (DRIP) | AVBP - No DRIP | |
|---|---|---|
| Current Price | $13.01 | $13.01 |
| Start Shares | 768.64 | 768.64 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 768.64 | 768.64 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $3.81 | $13.01 |
| Total Dividends | $0 | $0 |
| Final Value | $2,927 | $10,000 |
NOTE: Above numbers are our estimate based on AVBP's Dividend and Price CAGR over past 2.8 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
ArriVent BioPharma, Inc. (AVBP) had its IPO on , and is traded on NASDAQ stock exchange.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.
AVBP website: https://arrivent.com
DCF model unavailable for AVBP — no fundamentals on file (ETFs and funds are not modelable).
